Mettler Toledo vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Columbus OH precision instruments (NYSE: MTD) Q4 2024 revenue $1.045B (+12%), adjusted EPS $12.41 (+32%); global market leader lab balances and food inspection, pharma/biopharma lab destocking recovery competing with Sartorius.
About
Mettler-Toledo International Inc. is a Columbus, Ohio-based precision instruments and services company — publicly traded on the New York Stock Exchange (NYSE: MTD) as an S&P 500 Health Care component — manufacturing and marketing the world's most comprehensive range of weighing instruments and precision analytical measurement devices for laboratory, industrial, and food retail applications through approximately 18,000 employees in 40 countries. Mettler-Toledo's product portfolio spans laboratory balances and analytical instruments (used in pharmaceutical R&D and quality control), industrial scales and process analytics (used in chemical, food, and beverage manufacturing), pharmaceutical inspection systems (tablet and capsule inspection lines), food inspection equipment (X-ray and metal detection systems, checkweighers), and retail weighing solutions (supermarket scales). In Q4 2024, Mettler-Toledo reported revenue of $1.045 billion (+12% year-over-year) and adjusted EPS of $12.41 (+32% over the prior-year $9.40) — demonstrating the company's operational leverage as volume returned following the laboratory instruments market's destocking correction. CEO Patrick Kaltenbach has led Mettler-Toledo since 2020, maintaining the company's premium pricing strategy and capital return program (no dividend; all free cash flow directed to share repurchases that have reduced the share count by approximately 50% over the past decade). Mettler-Toledo operates as a category leader in precision weighing with 30%+ global market share and consistently achieves operating margins of 28-30%.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.